About: Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
Creator	Behera, Sumita Ledford, Dennis Singam, Rajeswari Hellermann, Gary Jena, Prasanna Lockey, Richard Mohapatra, Shyam
source	Medline; PMC
abstract	BACKGROUND: Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in infants and is a risk factor for the development of asthma. Allergic asthmatics are more susceptible to RSV infection and viral exacerbation. METHODS: Since the effectiveness of corticosteroids in treating RSV infection has been controversial, we tested fluticasone propionate (FP) and salmeterol (Sal) alone versus FP plus Sal (FPS) on RSV-induced airway inflammation. Mice were sensitized and challenged with ovalbumin (OVA) and infected with RSV. Following infection they were treated with FP, Sal, or FPS intranasally and airway hyperreactivity (AHR), inflammation and RSV titers were examined. RESULTS: The group treated with FPS showed significantly lower AHR compared to the group treated with FP or Sal alone. The group treated with FP alone showed slightly decreased (non-significant) AHR compared to controls. Treatment with FPS resulted in significant decreases in the percentage of eosinophils and neutrophils in bronchoalveolar lavage fluid and in lung pathology compared to FP or Sal. FP alone decreased eosinophils but not neutrophils or lymphocytes, while Sal alone decreased eosinophils and neutrophils but not lymphocytes. FPS treatment of mice infected with RSV in the absence of allergen sensitization resulted in a 50% decrease of RSV titer in the lung and a reduction in neutrophils compared to FP or Sal. CONCLUSION: Together, these results indicate that fluticasone in combination with salmeterol is a more effective treatment for decreasing airway hyperreactivity and inflammation than either of them alone in allergen-sensitized, RSV-infected mice.
has issue date	2006-05-23(xsd:dateTime)
bibo:doi	10.1186/1743-422x-3-32
bibo:pmid	16719922
has license	cc-by
sha1sum (hex)	b1f86a8d26afcb49621b2b3aba8eaf1851b95315
schema:url	https://doi.org/10.1186/1743-422x-3-32
resource representing a document's title	Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice
has PubMed Central identifier	PMC1488829
has PubMed identifier	16719922
schema:publication	Virol J
resource representing a document's body	covid:b1f86a8d26afcb49621b2b3aba8eaf1851b95315#body_text
is schema:about of	named entity 'RSV INFECTION' named entity 'DEVELOPMENT' named entity 'BRONCHIOLITIS' named entity 'MAJOR' named entity 'RSV INFECTION' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'VIRAL' named entity 'EXACERBATION' named entity 'ALLERGIC' named entity 'ASTHMA' named entity 'RISK FACTOR' named entity 'MICE' named entity 'JOURNAL ' named entity 'SALMETEROL' named entity 'EITHER' named entity 'COMBINED' named entity 'FLUTICASONE PROPIONATE' named entity 'ALLERGEN' named entity 'BACKGROUND' named entity 'IS A' named entity 'SUSCEPTIBLE' named entity 'INFECTION' named entity 'INFANTS' named entity 'VIROLOGY' named entity 'CAUSE' covid:arg/b1f86a8d26afcb49621b2b3aba8eaf1851b95315 named entity 'bronchiolitis' named entity 'Respiratory syncytial virus' named entity 'asthma' named entity 'Allergic' named entity 'MgSO' named entity 'bronchiolitis' named entity 'fluticasone propionate and salmeterol' named entity 'Apoptosis' named entity 'cytopathic effect' named entity 'RSV' named entity 'nebulized' named entity 'IL-6' named entity '14,000' named entity 'hematoxylin and eosin' named entity 'cellular infiltration' named entity 'lung inflammation' named entity 'IFN-γ' named entity 'IACUC' named entity 'IL-10' named entity 'RSV infection' named entity 'wheeze' named entity 'CD4 +' named entity 'monotherapy' named entity 'RSV infection' named entity 'eosinophils' named entity 'bronchiolitis' named entity 'lymphocytes' named entity 'bronchiolitis' named entity 'ICAM-1' named entity 'PBS' named entity 'eosinophil' named entity 'chemokines' named entity 'prophylactically' named entity 'IFN-γ' named entity 'asthma exacerbations' named entity 'CD3' named entity 'RSV' named entity 'Staining' named entity '7.5' named entity 'long-acting β2 agonist' named entity 'prophylactic' named entity 'RSV' named entity 'inflammation' named entity 'homogenates' named entity 'pathogen' named entity 'OVA' named entity 'BALB/c' named entity 'CD3' named entity 'IL-10'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software